Credit and interest ratesnegative · 4 filings
“The cash component of interest expense (income) is attributable to borrowings under our term loan as well as interest received from various interest-bearing bank accounts.”10-Q · Mar 17, 2026 ↗
Kestra Medical Technologies, Ltd.
KMTS
Market read
Kestra Medical Technologies, Ltd.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Company-2.7% todayVolume comparison unavailable
Market group0 of 19 activeConsumer Health & Finance · unavailable
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- KMTS's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if KMTS's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- KMTS's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods3
Price observations319
Usable filing statements84
Verified relationships5
Evidence supporting the case
- Latest annual revenue changed +59.0% year over year.
- Operating margin changed +36.2 percentage points in the latest annual period.
- Net margin changed +51.9 percentage points in the latest annual period.
- Supply chain and availability has repeated favorable evidence across 4 filings.
Evidence challenging the case
No qualifying adverse evidence was identified; that is not proof there is no downside.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
23.536m+1.1%12m+30.7%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2024-04-30$27.8M—$-5.07—
2025-04-30$59.8M+115.1%$-5.13+23.6%
2026-04-30$95.1M+59.0%$-2.43—
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposurepositive · 4 filings
“We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and improved wearability.”10-Q · Mar 17, 2026 ↗
Supply chain and availabilitypositive · 4 filings
“The cash component of interest expense (income) is attributable to borrowings under our term loan as well as interest received from various interest-bearing bank accounts.”10-Q · Mar 17, 2026 ↗
Product pipeline and R&Dmixed · 2 filings
“We expect our expenses to continue to increase as our business grows, including as a result of our ongoing efforts to grow our sales and commercial organization, increase our brand awareness through programmatic and industry-specific advertising, conduct clin…”10-K · Jul 17, 2025 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
22.90-2.7% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for KMTS. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for KMTS. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind KMTS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
VOYAVoya Financial, Inc.competitorFeb 20, 2026 ▾
“Primary competitors to our Wealth Management business include LPL, SagePoint Financial, Kestra, Waddell & Reed, Securities America and Commonwealth.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
KMTS is currently a Follower in the organic co-movement group Consumer Health & Finance. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for KMTS; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.